logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Clears Pluristem's Phase II Clinical Trial In Intermittent Claudication

Pluristem Therapeutics Inc. (PSTI) announced that the United States Food and Drug Administration or FDA has granted the company clearance to start a Phase II clinical trial using the company's PLX-PAD cell product candidate for the treatment of Intermittent Claudication or IC, a subset of peripheral artery disease or PAD.

Pluristem's IC Phase II trial will evaluate the safety and efficacy of two doses (150x106 and 300x106) of PLX-PAD cells versus placebo administered via two intramuscular injections (day one and week twelve post initial injection).

The company noted that the study population will be comprised of 132 patients (44 in each cohort) with IC, Fontaine class IIb; Rutherford category 2-3, in approximately 10 U.S. clinical sites.

The primary efficacy end point of the trial will be the change in the Maximal Walking Distance from baseline during an Exercise Treadmill Test. Secondary endpoints will include hemodynamics and quality of life measurements. Safety parameters will also be assessed.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Consumer Financial Protection Bureau or CFPB filed a lawsuit Wednesday against Navient, the nation's largest student loan company, alleging that it failed borrowers at at every stage of repayment. In response, Navient, in a statement, said the allegations are unfounded, and with political motivations, and rejected CFPB ultimatum to settle by Inauguration Day or be sued. Lilly is all set to acquire CoLucid Pharma for $46.50 per share in cash or approximately $960 million. Shares of Netflix Inc. (NFLX), Monday gained over 8 percent in extended trading session after the online-video streaming service reported a fourth-quarter profit that trumped analysts estimates, driven largely by higher-than-expected subscriber additions both domestically and internationally. Netflix...
comments powered by Disqus
Follow RTT